TGTX · Company research

TG Therapeutics, Inc.

3 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

ConferenceTGTXTGH2 2026

TG presents data on ublituximab (BRIUMVI IV) for relapsing multiple sclerosis (Day 1 + Day 15 combined dosing regimen) at a medical meeting in the second half of 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.

More details

Entry

Full Phase 3 ENHANCE trial results presentation (IV BRIUMVI rapid dosing) · Data presented at a medical meeting

Drug

ublituximab (BRIUMVI IV)

For

relapsing multiple sclerosis (Day 1 + Day 15 combined dosing regimen)

Stage

Phase 3 · the last stage before a drug can be approved

When

H2 2026 · the company gave a window, not a day

Source note

Company plans to present full ENHANCE results later in 2026 following positive topline announcement.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
TGTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsTGTXTGH2 2026

TG expects to report results from its Phase 1 study of azercabtagene zapreleucel (azer-cel, allogeneic CD19 CAR-T) for progressive multiple sclerosis in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details

Entry

Preliminary Phase 1 azer-cel data in progressive MS · Clinical trial results (readout / topline data)

Drug

azercabtagene zapreleucel (azer-cel, allogeneic CD19 CAR-T)

For

progressive multiple sclerosis

Stage

Phase 1 · an early safety study in a small group of people

When

H2 2026 · the company gave a window, not a day

Source note

Company guidance: present preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
TGTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsTGTXTGQ4 2026

TG expects to report results from its Phase 3 study of ublituximab subcutaneous (BRIUMVI SC) for relapsing multiple sclerosis in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

Subcutaneous BRIUMVI Phase 3 topline now year-end 2026 or early 2027 · Clinical trial results (readout / topline data)

Drug

ublituximab subcutaneous (BRIUMVI SC)

For

relapsing multiple sclerosis

Stage

Phase 3 · the last stage before a drug can be approved

When

Q4 2026 · the company gave a window, not a day

Source note

existing TGTX|readout|2026-Q4 SC BRIUMVI item; Q2 2026 PR (Aug 3, 2026) now guides topline to year-end 2026/first quarter 2027, i.e. may slip into 2027-Q1. Date kept at 2026-Q4 as the earliest stated window.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
TGTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

Trial resultsTGTXTGJun 9, 2026

TG reported results from its Phase 1 study of BRIUMVI (ublituximab-xiiy) for myasthenia gravis on Jun 9, 2026. The study met its main goal.

More details

Entry

Positive Phase 1 BRIUMVI data in myasthenia gravis; Phase 2 initiated · Clinical trial results (readout / topline data)

Drug

BRIUMVI (ublituximab-xiiy)

For

myasthenia gravis

Stage

Phase 1 · an early safety study in a small group of people

When

Jun 9, 2026

Source note

TG reported positive topline Phase 1 data for BRIUMVI in myasthenia gravis (82% achieved MG-ADL MCID, mean 4.6-point improvement) and started a potentially registration-directed randomized Phase 2 of IV BRIUMVI as maintenance after efgartigimod induction.

Checked

Checked by a person when it was added

Verify it

Source: stocktitan.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
TGTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsTGTXTGJun 3, 2026

TG reported results from its Phase 1 study of subcutaneous BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis on Jun 3, 2026. The study met its main goal.

More details

Entry

Phase 1 subcutaneous BRIUMVI PK/PD de-risks ongoing Phase 3 · Clinical trial results (readout / topline data)

Drug

subcutaneous BRIUMVI (ublituximab-xiiy)

For

relapsing forms of multiple sclerosis

Stage

Phase 1 · an early safety study in a small group of people

When

Jun 3, 2026

Source note

Subcutaneous ublituximab showed >60% mean bioavailability versus IV and PK modeling supporting non-inferior 24-week exposure for both Phase 3 dosing regimens, with no new safety signals. Filed on an 8-K as a material event; Phase 3 topline guided to year-end 2026 or early 2027.

Checked

Checked by a person when it was added

Verify it

Source: sec.gov ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
TGTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsTGTXTGMay 27, 2026

TG reported results from its Phase 3 study of BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis on May 27, 2026. The study met its main goal.

More details

Entry

Phase 3 ENHANCE met primary endpoint: single Day 1 BRIUMVI infusion · Clinical trial results (readout / topline data)

Drug

BRIUMVI (ublituximab-xiiy)

For

relapsing forms of multiple sclerosis

Stage

Phase 3 · the last stage before a drug can be approved

When

May 27, 2026

Source note

ENHANCE showed bioequivalent 16-week exposure (GMR ~1.0, 90% CI within 0.80-1.25) between a consolidated single 600 mg Day 1 infusion and the approved Day 1/Day 15 split regimen, with no new safety signals. TG targeted a supplemental BLA in 2H 2026.

Checked

Checked by a person when it was added

Verify it

Source: sec.gov ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
TGTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to TGTX.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.